EGFR-TKI 已成为 EGFR 突变晚期非小细胞肺癌（NSCLC）患者的标准治疗方案[1]，然而，约 2%~5% 的初治 EGFR 突变晚期 NSCLC 患者合并原发 MET 扩增，且接受 EGFR-TKI ...

Lung cancer cases are increasing in people who have never smoked, especially in women, a new study by the World Health Organization’s cancer agency has found.

国家药品监督管理局（NMPA）官网发布药品批准证明文件送达信息，文件中显示已于2025年2月8日正式批准 埃万妥单抗注射液（锐珂®）与卡铂和培美曲塞联合给药，用于经检测确认携带表皮生长因子受体 ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

Yeah, so the EGFR mutation lung cancer field has really expanded. We usually think about EGFR as the classical mutation, deletion 19 and 858R mutation. But in the last, I will say, five to 10 ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

It has been recommended by the National Institute for Health and Care Excellence (NICE) as an additional treatment for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC).

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...